Latest News

Biogen Soars 46% on Alzheimer’s Drug Trial. Mizuho Raises the Stock to Buy.

0

Biogen Soars 46% on Alzheimer’s Drug Trial. Mizuho Says the Stock Is a Buy. | Barron’s


Biogen

shares were soaring Wednesday after the biopharmaceutical company said that its experimental Alzheimer’s drug with Japan-based partner 


Eisai

showed promising results.

Guggenheim Securities analyst Yatin Suneja called the data “a new dawn for Alzheimer’s treatment.”

Biogen stock explodes higher after potential ‘mega blockbuster’ Alzheimer’s drug study

Previous article

10 Stocks Are Screaming Buys As Monster Rally Nears, Analysts Say

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News